AlphaCrest Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

AlphaCrest Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-852	Closed	-$198K	–	1246
2022 Q1	$198K	Buy	852 +373	+78%	+$119K	0.01%	1213
2021 Q4	$189K	Buy	+479	New	+$202K	0.01%	1338
2021 Q2	–	Sell	-1,224	Closed	-$439K	–	1219
2021 Q1	$439K	Buy	+1,224	New	+$541K	0.02%	859
2020 Q3	–	Sell	-520	Closed	-$189K	–	1082
2020 Q2	$189K	Buy	+520	New	+$131K	0.03%	848

Other funds holding ATRA

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AlphaCrest Capital Management's ATRA Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 852 shares — an estimated $198K sold.

AlphaCrest Capital Management first reported a position in ATRA in Q2 2020 and held it in 4 quarters. The position peaked at $439K in Q1 2021. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

AlphaCrest Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 852 Atara Biotherapeutics shares in Q2 2022, an estimated $198K.
AlphaCrest Capital Management first reported a position in Atara Biotherapeutics in Q2 2020 and held it in 4 quarters.
AlphaCrest Capital Management's Atara Biotherapeutics position peaked at $439K in Q1 2021.
134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.